kneat.com (TSE:KSI - Get Free Report) is set to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of C($0.05) per share for the quarter.
kneat.com (TSE:KSI - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported C($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of C($0.04). The firm had revenue of C$11.68 million for the quarter, compared to analysts' expectations of C$11.45 million. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%.
kneat.com Price Performance
Shares of TSE KSI traded down C$0.10 during mid-day trading on Thursday, hitting C$4.70. 15,458 shares of the company's stock traded hands, compared to its average volume of 55,814. The company's 50-day moving average is C$4.76 and its two-hundred day moving average is C$4.44. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50. The company has a market capitalization of C$404.20 million, a P/E ratio of -29.50, a PEG ratio of 597.67 and a beta of 1.08. kneat.com has a 1 year low of C$2.68 and a 1 year high of C$5.17.
Analysts Set New Price Targets
Several equities analysts recently commented on KSI shares. Cibc World Mkts upgraded shares of kneat.com to a "strong-buy" rating in a report on Tuesday. Ventum Cap Mkts upgraded shares of kneat.com to a "strong-buy" rating in a report on Wednesday, August 7th. Finally, CIBC set a C$6.00 target price on shares of kneat.com and gave the stock an "outperform" rating in a research report on Tuesday.
Check Out Our Latest Stock Report on KSI
kneat.com Company Profile
(
Get Free Report)
kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.
See Also
Before you consider kneat.com, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and kneat.com wasn't on the list.
While kneat.com currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
